Given that mTOR inhibition alone does not address PI3K-driven hyperglycemia, a key metabolic challenge in PI3K-targeted therapies, selective p110α inhibitors like GCT-007 may provide a more integrated approach to pathway suppression in DMG. This evidence concerns the gene PIK3CA and Hyperglycemia.